A Workflow for Rapid Sample Preparation and Exoglycosidase Characterization of N-Glycans in Antibodies

Significance of the topic

Protein glycosylation significantly affects biotherapeutic structure and function by modulating stability, solubility, immunogenicity, serum half-life, and protein–protein interactions.
Rapid and reproducible profiling of N-glycans is essential for quality control of monoclonal antibodies and other glycoprotein-based biopharmaceuticals.

Study objectives and overview

This application note describes a high-throughput workflow for rapid sample preparation and exoglycosidase-assisted characterization of N-glycans in human serum immunoglobulin G (IgG).
The goal is to streamline glycoprotein denaturation, enzymatic deglycosylation, fluorescent derivatization, and cleanup in a 96-well plate format to enable reproducible HILIC/FLD analysis and structural confirmation via sequential enzyme digestion.

Methodology and used instrumentation

Sample preparation is performed on a 96-well plate using the Agilent AdvanceBio Gly-X N-glycan prep with InstantPC kit, which comprises:

• Denaturation module: 3 min at 90 °C
• Deglycosylation module: 5 min at 50 °C with peptide-N-glycosidase
• Labeling module: 1 min at 50 °C with InstantPC reagent
• Cleanup module: on-matrix HILIC purification

Subsequent analysis and structural assignment involve:

• Hydrophilic interaction liquid chromatography with fluorescence detection (HILIC/FLD) on an Agilent 1260 Infinity II system
• AdvanceBio Glycan Mapping column (120 Å, 2.1 × 150 mm, 2.7 µm)
• Agilent OpenLab ChemStation software
• Calibration with an InstantPC maltodextrin ladder
• Exoglycosidase sequential digestions using sialidase A, β(1-4) galactosidase, and β-hexosaminidase for structural validation

Main results and discussion

The complete workflow is completed in approximately one hour and yields well resolved N-glycan profiles for human serum IgG.
Major glycan species identified include core-fucosylated agalactosylated (FA2), monogalactosylated (FA2G1), and digalactosylated (FA2G2) structures as well as sialylated forms such as FA2G2S1.
Good reproducibility was demonstrated across replicates, and exoglycosidase digestion patterns confirmed the proposed assignments.
The mild conditions preserve labile sialic acid linkages and support sensitive fluorescence detection.

Benefits and practical applications

This streamlined method offers:

• High-throughput sample preparation in 96-well plates
• Rapid turnaround (< 1 h) for routine glycan profiling
• High sensitivity and reproducibility for critical quality attribute monitoring of biotherapeutics
• Compatibility with automation in biopharmaceutical development and quality control laboratories

Future trends and potential applications

Emerging directions include integration with mass spectrometry detection for deeper structural analysis, further reduction of analysis time for point-of-care glycomics, and extension to diverse glycoprotein classes and biomarker discovery studies.
Advanced labeling chemistries and microfluidic platforms may enhance throughput and data quality in clinical and research settings.

Conclusion

The Agilent AdvanceBio Gly-X N-glycan prep with InstantPC kit provides a robust, rapid, and sensitive workflow for high-throughput N-glycan profiling and structural validation in antibodies.
This approach supports reliable monitoring of glycosylation CQAs in biopharmaceutical development.

References

1. Hebert DN The Intrinsic and Extrinsic Effects of N-Linked Glycans on Glycoproteostasis Nat Chem Biol 2014 10 902–910
2. Liu L Antibody Glycosylation and its Impact on the Pharmacokinetics and Pharmacodynamics of Monoclonal Antibodies and Fc-Fusion Proteins J Pharm Sci 2015 104 1866–1884
3. Melmer M HILIC analysis of fluorescence-labeled N-glycans from recombinant biopharmaceuticals Anal Bioanal Chem 2010 398 905–914
4. Ruhaak LR Glycan Labeling Strategies and Their Use in Identification and Quantification Anal Bioanal Chem 2010 397 3457–3481
5. Xie Y High-Throughput and High-Sensitivity N-Glycan Profiling a Platform for Biopharmaceutical Development and Disease Biomarker Discovery Anal Biochem